A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

• Status: Completed
• Trial end date: 2016-12-21
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Global Development, Inc.
• Treatments: Albumin-Bound Paclitaxel; BB 1101; Bortezomib; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Erlotinib Hydrochloride; Paclitaxel

Criteria

Inclusion Criteria:

• Subject must currently be participating in an Astellas sponsored linsitinib trial that has ended with respect to the overall study analysis.

• Subject must not have met criteria for discontinuation or have progressed on the current linsitinib study in which they are participating.

• Subject must be deriving benefit from continued treatment.